Description: This panel will present the perspectives of state government, federal government, and health maintenance organizations HMOs with respect to Medicaid risk contracting. From the Record of the Society of Actuaries, Vol. 21, No. 4b.

Description: This session is about group dental coverage, issues in benefit design, managed care [dental HMO & PPO] and market trends. From Record of Society of Actuaries Vol. 19, No. 1B.

Description: This session at the 1998 Valuation Actuary Symposium risk based capital for health organizations with focus on a new formula for managed care organizations and companies.

Description: 1998 Valuation Actuary Symposium. The speakers presented a case study on long-term-care gross premium valuations, GPV from an individual disability income perspective, and a case study for a medical GPV.

Description: This session is about individual medical and regulatory issues, loss-ratio requirements, form and rate approval, compliance and reporting issues. From Record of Society of Actuaries Vol. 19, No. 4B.

Description: At the beginning of 1999, a new model regulation is expected to be approved by the National Association of Insurance Commissioners and will regulate risk-based capital for managed care organizations. Panelists describe the regulation and offer insights into the why, wherefore, and whereto. They consider the potential impact of the new regulation on the current life insurance company risk-based capital regulation that governs traditional health carriers.

Description: Panelists discuss the use of predictive modeling for health insurance in underwriting, rating, case management, etc. Panelists also discuss practical issues associated with implementing predictive modeling. From the 2002 Record of Society of Actuaries, Volume 28, No. 2. Session 99OF of the San Francisco Spring Meeting.

Description: This session 99PD of the New Orleans Annual Meeting summary: Insurers today are looking for new ways to use currently available experience data to better predict future costs. Both the federal and state governments are looking at the possibility of using prescription drug data because it is more available and often of higher quality than other experience data. From the Record of the Society of Actuaries, Volume 27, No. 3, Session 99PD.